IQN Path is pleased to announce and endorse two new CBQAReadout modules including VENTANA PD-L1 (SP142) Assay, NSCLC, atezolizumab (3 hours) and VENTANA PD-L1 (SP263) Assay, NSCLC, nivolumab (3 hours). VENTANA PD-L1 (SP142) Assay, triple negative breast cancer, atezolizumab and nab-paclitaxel (2 hours) module will be open on June 1st, 2020. We will update you regularly read more…